JP2018502572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502572A5 JP2018502572A5 JP2017534345A JP2017534345A JP2018502572A5 JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5 JP 2017534345 A JP2017534345 A JP 2017534345A JP 2017534345 A JP2017534345 A JP 2017534345A JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- bispecific antibody
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562099236P | 2015-01-02 | 2015-01-02 | |
| US62/099,236 | 2015-01-02 | ||
| US201562200363P | 2015-08-03 | 2015-08-03 | |
| US62/200,363 | 2015-08-03 | ||
| US201562261609P | 2015-12-01 | 2015-12-01 | |
| US62/261,609 | 2015-12-01 | ||
| PCT/US2015/068238 WO2016109774A1 (en) | 2015-01-02 | 2015-12-31 | Bispecific antibodies against plasma kallikrein and factor xii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Division JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502572A JP2018502572A (ja) | 2018-02-01 |
| JP2018502572A5 true JP2018502572A5 (OSRAM) | 2019-02-14 |
| JP6744313B2 JP6744313B2 (ja) | 2020-08-26 |
Family
ID=56285069
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534345A Active JP6744313B2 (ja) | 2015-01-02 | 2015-12-31 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11390687B2 (OSRAM) |
| EP (1) | EP3240570B1 (OSRAM) |
| JP (4) | JP6744313B2 (OSRAM) |
| KR (2) | KR20240091031A (OSRAM) |
| CN (2) | CN107405399B (OSRAM) |
| AU (2) | AU2015373910B2 (OSRAM) |
| CA (1) | CA2972800A1 (OSRAM) |
| CO (1) | CO2017007123A2 (OSRAM) |
| EA (1) | EA201791527A1 (OSRAM) |
| IL (2) | IL253180B2 (OSRAM) |
| MX (2) | MX2017008541A (OSRAM) |
| NZ (1) | NZ771568A (OSRAM) |
| WO (1) | WO2016109774A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3240570B1 (en) | 2015-01-02 | 2025-09-24 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and factor xii |
| EA201890340A1 (ru) * | 2015-07-21 | 2018-09-28 | Дайэкс Корп. | Моноклональное антитело-ингибитор фактора xiia |
| BR112019005172A2 (pt) * | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| EP3668893A4 (en) * | 2017-08-16 | 2021-08-04 | Dragonfly Therapeutics, Inc. | PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1 |
| AU2018350992A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| EP3737949A1 (en) * | 2018-01-12 | 2020-11-18 | Genzyme Corporation | Methods for the quantitation of polypeptides |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| MX2020013158A (es) * | 2018-06-08 | 2021-04-29 | Modalis Therapeutics Corp | Proteina cas9 modificada y uso de la misma. |
| CN112996910A (zh) * | 2018-07-11 | 2021-06-18 | 动量制药公司 | 与靶向PD-L1的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| MX2021001510A (es) * | 2018-08-08 | 2021-07-02 | Dragonfly Therapeutics Inc | Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores. |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| US20210355187A1 (en) * | 2018-10-24 | 2021-11-18 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| US12077585B2 (en) * | 2019-07-26 | 2024-09-03 | Janssen Biotech, Inc. | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| EP4236974A2 (en) * | 2020-10-29 | 2023-09-06 | RegenxBio Inc. | Vectorized factor xii antibodies and administration thereof |
| CN114790246A (zh) * | 2021-01-25 | 2022-07-26 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| CN114790245A (zh) * | 2021-01-25 | 2022-07-26 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| KR20230160389A (ko) * | 2021-04-22 | 2023-11-23 | 광동 파폰 바이오파마 인크. | 이중 특이성 다기능 융합 폴리펩티드 |
| WO2024238407A2 (en) * | 2023-05-12 | 2024-11-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of treating dilated cardiomyopathy and heart failure |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| NZ276305A (en) | 1993-11-16 | 1997-10-24 | Depotech Corp | Controlled release vesicle compositions |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| GB9609262D0 (en) | 1996-05-02 | 1996-07-03 | Isis Innovation | Peptide library and method |
| AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
| AU3734900A (en) | 1999-03-09 | 2000-09-28 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CN101255196A (zh) * | 2002-06-28 | 2008-09-03 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| AU2005318464B2 (en) | 2004-12-23 | 2012-02-23 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization |
| GB0500487D0 (en) | 2005-01-11 | 2005-02-16 | Axis Shield Diagnostics Ltd | Forms of factor XIIa |
| US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| TWI496582B (zh) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| AU2009335643B2 (en) | 2008-12-18 | 2014-05-29 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| TR201802772T4 (tr) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| IL269565B2 (en) * | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| RS66465B1 (sr) | 2011-07-22 | 2025-02-28 | Csl Behring Gmbh | Inhibitorna monoklonska antitela protiv faktora xii/xiia i njihove upotrebe |
| JP5653860B2 (ja) | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
| US20150299313A1 (en) | 2011-10-05 | 2015-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain |
| PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| SI2847228T1 (sl) | 2012-05-10 | 2018-11-30 | Bayer Pharma Aktiengesellschaft | Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe |
| US20140038204A1 (en) | 2012-07-31 | 2014-02-06 | Baxter Healthcare S.A. | Selective measurement of active human protease coagulation factors |
| WO2014089493A1 (en) | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
| PL2946206T3 (pl) | 2013-01-20 | 2019-07-31 | Dyax Corp. | Ocena, testy i leczenie zaburzeń mediowanych przez PKAL |
| EP2970502A4 (en) * | 2013-03-15 | 2016-11-30 | Dyax Corp | ANTI-PLASMA KALLIKREIN ANTIBODY |
| PL3013366T3 (pl) * | 2013-06-28 | 2022-01-17 | Csl Behring Gmbh | Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1 |
| CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| EP3240570B1 (en) | 2015-01-02 | 2025-09-24 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and factor xii |
| EA201890340A1 (ru) | 2015-07-21 | 2018-09-28 | Дайэкс Корп. | Моноклональное антитело-ингибитор фактора xiia |
| EP3263803B1 (en) | 2016-06-30 | 2019-08-14 | ABB Schweiz AG | Substation |
-
2015
- 2015-12-31 EP EP15876336.7A patent/EP3240570B1/en active Active
- 2015-12-31 NZ NZ771568A patent/NZ771568A/en unknown
- 2015-12-31 AU AU2015373910A patent/AU2015373910B2/en active Active
- 2015-12-31 US US15/541,066 patent/US11390687B2/en active Active
- 2015-12-31 JP JP2017534345A patent/JP6744313B2/ja active Active
- 2015-12-31 IL IL253180A patent/IL253180B2/en unknown
- 2015-12-31 MX MX2017008541A patent/MX2017008541A/es unknown
- 2015-12-31 CN CN201580075633.1A patent/CN107405399B/zh active Active
- 2015-12-31 IL IL298086A patent/IL298086B2/en unknown
- 2015-12-31 KR KR1020247017566A patent/KR20240091031A/ko active Pending
- 2015-12-31 WO PCT/US2015/068238 patent/WO2016109774A1/en not_active Ceased
- 2015-12-31 CA CA2972800A patent/CA2972800A1/en active Pending
- 2015-12-31 EA EA201791527A patent/EA201791527A1/ru unknown
- 2015-12-31 KR KR1020177021610A patent/KR102670705B1/ko active Active
- 2015-12-31 CN CN202210054884.3A patent/CN114316061B/zh active Active
-
2017
- 2017-06-26 MX MX2024000317A patent/MX2024000317A/es unknown
- 2017-07-17 CO CONC2017/0007123A patent/CO2017007123A2/es unknown
-
2020
- 2020-07-30 JP JP2020128994A patent/JP7003347B2/ja active Active
-
2021
- 2021-09-16 JP JP2021150755A patent/JP7241827B2/ja active Active
-
2022
- 2022-02-17 AU AU2022201076A patent/AU2022201076B2/en active Active
- 2022-06-13 US US17/838,769 patent/US12240918B2/en active Active
-
2023
- 2023-03-07 JP JP2023035060A patent/JP7635285B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502572A5 (OSRAM) | ||
| JP2020186248A5 (OSRAM) | ||
| CN106459220B (zh) | 适用于高通量筛选的新的双特异性形式 | |
| US11286312B2 (en) | Multispecific antibodies | |
| JP2016533174A5 (OSRAM) | ||
| KR102282691B1 (ko) | 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법 | |
| JP7203800B2 (ja) | ヌクレオチド・ライブラリー | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2017512063A5 (OSRAM) | ||
| JP2017529067A5 (OSRAM) | ||
| CN108473554A (zh) | 多特异性抗体 | |
| JP2020500510A5 (OSRAM) | ||
| JP2014518883A5 (OSRAM) | ||
| JP2014521313A5 (OSRAM) | ||
| KR20190111946A (ko) | 1가 항-프로페르딘 항체 및 항체 단편 | |
| JP2019506839A5 (OSRAM) | ||
| JP2018512124A5 (OSRAM) | ||
| CN111526887A (zh) | 用于使血清中的蛋白质半衰期增加的组合物和方法 | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| JP6247646B2 (ja) | ヒト化抗ｈｍｇｂ１抗体もしくはその抗原結合性断片 | |
| Henry et al. | A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders | |
| Aoki et al. | Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor | |
| CN107073093A (zh) | 亲和蛋白及其用途 | |
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides |